康惠制药(603139) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥202,931,449.18, representing a year-on-year increase of 53.60%[3] - The net profit attributable to shareholders for the third quarter was a loss of ¥3,377,492.68, a decrease of 244.34% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the third quarter was a loss of ¥6,729,675.76, a decrease of 898.21% year-on-year[3] - The basic earnings per share for the third quarter was -¥0.04, a decrease of 300.00% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2023 reached CNY 472,228,266.33, an increase from CNY 375,140,799.38 in the same period of 2022, representing a growth of approximately 25.9%[23] - Net profit for the third quarter was CNY 1,105,939.76, a significant decrease from CNY 16,131,708.24 in the same quarter last year, representing a decline of about 93.2%[27] - Total profit for the period was CNY 2,720,313.17, a significant drop from CNY 19,929,242.06 in the previous year, indicating a decline of approximately 86.4%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,138,854,896.09, an increase of 17.41% compared to the end of the previous year[5] - As of September 30, 2023, total current assets amounted to CNY 828,767,040.78, up from CNY 580,930,688.32 at the end of 2022, indicating a growth of about 42.6%[15] - The company's inventory increased significantly to CNY 255,316,910.45 from CNY 122,766,649.72, reflecting a growth of approximately 108%[17] - Short-term borrowings surged to CNY 252,186,240.07, compared to CNY 83,844,711.95 at the end of 2022, marking an increase of about 200%[19] - Total liabilities as of September 30, 2023, were CNY 1,065,014,818.63, compared to CNY 795,754,114.03 at the end of 2022, representing an increase of approximately 33.9%[21] - The company's total assets reached CNY 2,138,854,896.09, up from CNY 1,821,698,824.24 at the end of 2022, indicating a growth of about 17.4%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥99,227,024.09, a decrease of 311.27% year-on-year[3] - Operating cash flow for the period was negative at CNY -99,227,024.09, contrasting with a positive cash flow of CNY 46,967,223.22 in the same period last year[28] - The total cash inflow from operating activities was CNY 429,735,988.71, slightly down from CNY 437,065,260.94 in the previous year, a decrease of about 1.5%[28] - The net cash flow from investment activities was -32,816,091.39, compared to -46,516,002.64 in the previous period, indicating an improvement[30] - Total cash inflow from financing activities was 308,892,010.87, up from 187,173,510.23, reflecting a significant increase in financing[30] - Cash outflow for debt repayment was 152,063,898.37, compared to 90,902,747.96 in the previous period, showing an increase in debt servicing[30] - The net cash flow from financing activities was 128,396,470.46, compared to 68,605,879.86, indicating a stronger financing position[30] - The ending balance of cash and cash equivalents was 202,626,165.81, down from 260,703,686.58, reflecting a decrease in liquidity[30] Expenses and Costs - Total operating costs for the period reached CNY 470,567,191.27, an increase from CNY 362,893,894.67 in the previous period, reflecting a growth of approximately 29.8%[25] - Research and development expenses totaled CNY 7,483,361.02, down from CNY 9,833,820.15 in the previous year, showing a reduction of about 23.9%[25] - The company incurred financial expenses of CNY 9,498,247.25, which is an increase from CNY 3,518,752.15 in the previous year, representing an increase of about 169.5%[25] - The company reported a significant increase in sales expenses, which amounted to CNY 86,837,266.20, down from CNY 102,702,169.56 in the previous year, indicating a decrease of approximately 15.5%[25] Future Outlook - The company attributed the increase in operating revenue primarily to an expanded consolidation scope[7] - The company plans to address the losses from its subsidiary, Shandong Youbang, which contributed to the decline in net profit[7] - The company has not provided specific guidance for future performance or new product developments in the available documents[14]